Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...

Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...

Response-guided axillary treatment using an approach known as the MARI protocol can safely spare many women with node-positive breast cancer from axillary lymph node dissection (ALND) after ...

The detection and analysis of sentinel lymph nodes (SLNs) have transformed axillary staging in breast cancer. By identifying the first draining lymph node, clinicians can determine nodal involvement ...

SAN ANTONIO -- Patients with early breast cancer who skipped axillary lymph node dissection (ALND) lived just as long as those who underwent sentinel lymph node biopsy (SLNB), the randomized INSEMA ...

Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

Please provide your email address to receive an email when new articles are posted on . Intraoperative pathology assessment led to increased use of both axillary lymph node dissection and axillary ...

Patients with breast cancer that has started to spread to the lymph nodes in the armpit can safely avoid extensive removal of the lymph nodes if their treatment is tailored to their response to cancer ...

Please provide your email address to receive an email when new articles are posted on . Patients with breast cancer had similar survival whether they underwent completion axillary lymph node ...

Dr. Ko Un “Clara” Park and Dr. Mylin Torres present the latest evidence-based changes to the SLNB in early-stage breast cancer guideline. They discuss the practice-changing trials that led to the ...